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Abstract
Background: Amyloid-related degenerative diseases are associated with the accumulation of misfolded proteins as amyloid
fibrils in tissue. In Alzheimer disease (AD), amyloid accumulates in several distinct types of insoluble plaque deposits, intracellular
Aβ and as soluble oligomers and the relationships between these deposits and their pathological significance remains unclear.
Conformation dependent antibodies have been reported that specifically recognize distinct assembly states of amyloids, including
prefibrillar oligomers and fibrils.
Results: We immunized rabbits with a morphologically homogeneous population of Aβ42 fibrils. The resulting immune serum
(OC) specifically recognizes fibrils, but not random coil monomer or prefibrillar oligomers, indicating fibrils display a distinct
conformation dependent epitope that is absent in prefibrillar oligomers. The fibril epitope is also displayed by fibrils of other
types of amyloids, indicating that the epitope is a generic feature of the polypeptide backbone. The fibril specific antibody also
recognizes 100,000 × G soluble fibrillar oligomers ranging in size from dimer to greater than 250 kDa on western blots. The
fibrillar oligomers recognized by OC are immunologically distinct from prefibrillar oligomers recognized by A11, even though
their sizes overlap broadly, indicating that size is not a reliable indicator of oligomer conformation. The immune response to
prefibrillar oligomers and fibrils is not sequence specific and antisera of the same specificity are produced in response to
immunization with islet amyloid polypeptide prefibrillar oligomer mimics and fibrils. The fibril specific antibodies stain all types
of amyloid deposits in human AD brain. Diffuse amyloid deposits stain intensely with anti-fibril antibody although they are
thioflavin S negative, suggesting that they are indeed fibrillar in conformation. OC also stains islet amyloid deposits in transgenic
mouse models of type II diabetes, demonstrating its generic specificity for amyloid fibrils.
Conclusion: Since the fibril specific antibodies are conformation dependent, sequence-independent, and recognize epitopes
that are distinct from those present in prefibrillar oligomers, they may have broad utility for detecting and characterizing the
accumulation of amyloid fibrils and fibrillar type oligomers in degenerative diseases.
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Background
The accumulation of misfolded proteins and peptides as
amyloid deposits is a characteristic feature of many degen-
erative diseases, such as Alzheimer disease (AD), although
the pathological significance of these deposits remains
unclear. In AD, several different types of deposits contain-
ing the amyloid Aβ peptide have been recognized, includ-
ing dense cored, neuritic, diffuse and "cotton wool"
plaques [1-3]. Sites of intracellular accumulation of Aβ
have also been identified [4-8]. The relationships and
pathological significance of these accumulated deposits
remain a matter of debate. The pathological significance
of the fibrillar plaques is a matter of debate, since cogni-
tively normal aged individuals frequently have large
amounts of fibrillar deposits [9,10] and soluble oligo-
meric forms of Aβ correlate better with dementia [11,12].
It has also been suggested that the large insoluble amyloid
deposits may serve as reservoirs that release toxic soluble
oligomers [13]. It is widely accepted that diffuse amyloid
deposits are "non-fibrillar" based on a lack of binding of
fibril-specific dyes, like Congo red (CR) and ThioS. Senile
plaques and "cored" plaques stain with CR and ThioS,
while most diffuse plaques are negative [9]. Thioflavin
dyes have served as the basis for the development of con-
trast agents to image amyloid accumulation in vivo in
humans, although these dyes do not label diffuse plaques
in human AD brain nor the amyloid deposits that accu-
mulate in transgenic mouse models of AD.
Plaques have also been characterized immunologically.
Monoclonal antibodies specific for the carboxyl terminus
of Aβ indicate that diffuse plaques primarily contain Aβn-
42, while dense core and neuritic plaques contain both
Aβn-40 and Aβn-42 [14,15]. More recently, conforma-
tion-dependent antibodies have been reported that recog-
nize a generic epitope that is specific to many types of
amyloid fibrils and not soluble monomer regardless of
their sequences [16,17]. The WO1 antibody has been
reported to bind to a generic fibril epitope [17], but this
antibody also recognizes morphologically distinct "pro-
tofibrils" [18]. Whether this epitope recognized by WO1
is specific to the fibrillar state or is also displayed on pre-
fibrillar aggregates or oligomers has yet to be determined.
Other conformation dependent antibodies (A11) have
been reported that specifically recognize a generic epitope
common to prefibrillar oligomers and not fibrils, mono-
mers or natively folded precursor proteins [19]. These oli-
gomers are widely believed to represent a primary toxic or
pathological species and are called "prefibrillar" because
they kinetically precede fibril formation and disappear
after fibrils have formed [20,21]. While A11 stains small
focal or punctuate deposits in AD tissue, it does not stain
diffuse plaques or other plaque types, indicating that dif-
fuse deposits are not accumulations of prefibrillar oligom-
ers.
Here we report a conformation dependent, fibril specific
polyclonal antisera that recognizes a generic epitope that
is associated with amyloid fibrils and soluble fibrillar oli-
gomers that is distinct from prefibrillar oligomers. Like
other conformation dependent antibodies, it does not rec-
ognize natively folded APP or monomer. This antibody
may have considerable utility for localizing and quantitat-
ing fibril related aggregates in tissues and biological fluids.
Results
Fibril specificity of OC antisera
The specificity of OC antisera was examined by ELISA and
dot blot analysis of monomeric, prefibrillar oligomeric
and fibrillar Aβ and other types of amyloids (Fig. 1).
ELISA analysis indicates that OC is conformation depend-
ent and fibril specific because it recognizes Aβ fibrils, but
not Aβ prefibrillar oligomers or Aβ monomer (Fig. 1A).
OC recognizes a generic epitope that is associated with the
fibrillar amyloid state regardless of the sequence because
it reacts equally well with α-synuclein fibrils and islet
amyloid polypeptide (IAPP) fibrils. Dot blot analysis con-
firms that the fibril epitope of both Aβ and poly Q (Q36)
fibrils is recognized by OC and is complementary and
mutually exclusive with the generic prefibrillar epitope of
both Aβ and polyQ oligomers that is recognized by A11.
A11 does not recognize the fibrillar samples that stain
with OC, while OC does not stain the prefibrillar samples
recognized by A11 (Fig. 1B). The size distribution of Aβ
aggregates that are recognized by OC and A11 was deter-
mined by western blotting of fibrillar and prefibrillar oli-
gomer Aβ samples (Fig. 2). Aβ42 fibrils contain 6E10 and
4G8 reactive bands at the positions of 4.5 kDa monomer,
dimer, tetramer and a broad smear of aggregates up to the
top of the gel. Prefibrillar oligomer Aβ42 samples contain
A11 positive aggregates of the same approximate size
range as fibrils that are stained by 4G8, but the prefibrillar
oligomers are not stained by 6E10. We have previously
reported that 6E10 does not stain prefibrillar oligomers
prepared by dilution of a stock solution of Aβ42 in 100
mM NaOH in PBS, but it does recognize prefibrillar oli-
gomers formed in water at pH 2.5 and 6E10 recognizes
random coil monomer and amyloid fibrils [22]. These
results indicate that prefibrillar Aβ oligomers are poly-
morphic at the 6E10 epitope and that the Aβ monomer in
the prefibrillar oligomer preparation has a stable confor-
mation that is not reactive with 6E10. OC anti-fibril
antiserum stains the Aβ42 dimer band and higher aggre-
gates from fibrillar samples, but does not stain Aβ mono-
mer (Fig. 2). However, OC does not stain the prefibrillar
oligomer aggregates that are stained by A11. A11 stains
bands corresponding to tetramer and a broad distribution
of aggregates centred on a molecular weight of approxi-
mately 60 kDa, indicating that fibrillar oligomers are con-
formationally distinct from prefibrillar oligomers even
though their sizes are broadly overlapping. The size of theMolecular Neurodegeneration 2007, 2:18 http://www.molecularneurodegeneration.com/content/2/1/18
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bands detected by OC and A11 depend on the time of
aggregation with the size increasing with incubation time
(data not shown).
Characterization of soluble fibrillar oligomers
The fact that low MW species are recognized on western
blots by the OC anti fibril antibody, which are conforma-
tionally distinct from the prefibrillar oligomers that react
with A11, suggests that at least two distinct types of oli-
gomers exist: fibrillar oligomers and prefibrillar oligom-
ers. We characterized the solubility and size distribution
of OC positive oligomers under non-denaturing condi-
tions by ultracentrifugation and size exclusion chroma-
tography. Both fibril preparations prepared in HFIP/water
[19] and ADDL preparations prepared in DMSO and cold
F12 medium [23] contain a substantial amount of OC
positive 100,000 × G soluble material, suggesting that
they contain fibrillar oligomers (Fig. 3A). Samples pre-
pared by dilution of DMSO stock solutions of Aβ42 were
also fractionated by size exclusion chromatography and
the resulting fractions probed with OC. The results indi-
cate that a broad distribution of oligomer sizes from
approximately 8 kDa to 200 kDa is recognized by OC (Fig.
3B). These results are consistent with the sizes identified
by western blots (Fig. 2). The data suggest that these fibril-
lar oligomers have Aβ peptides arranged in the same con-
formation as in fibrils suggesting that they may represent
small pieces of fibrils or fibril nuclei.
Conformation dependent immune response is independent 
of antigen sequence
Since both A11 and OC recognize generic epitopes that do
not depend on a particular amino acid sequence, we
tested whether the immune response to other types of pre-
fibrillar oligomers and fibrils is also specific for generic
conformation dependent epitopes. We synthesized an oli-
gomer mimic of islet amyloid polypeptide (IAPP) by cou-
pling IAPP carboxy-terminal thioester to colloidal gold
particles as previously described [19]. We used IAPP oli-
gomer mimics and IAPP fibrils to immunize rabbits and
we characterized the specificity of the immune response
by dot blot. Immunization of rabbits with IAPP oligomer
mimics gives rise to a prefibrillar oligomer-specific
immune response that is indistinguishable from that
obtained with Aβ prefibrillar oligomer mimics (Fig. 4).
We call this serum I11 to indicate its derivation from IAPP
antigen and its similarity to A11. Like A11, I11 recognizes
prefibrillar oligomers derived from Aβ, α-synuclein and
IAPP, but not monomers or fibrils on dot blots (Fig. 4A).
Western blots of prefibrillar oligomer samples probed
Characterization of OC antiserum Figure 1
Characterization of OC antiserum. A. ELISA analysis. Plates were coated with homogenous samples of Aβ fibrils, Aβ 
monomer, Aβ prefibrillar oligomers, and α-synuclein and IAPP fibrils. The samples were reacted with OC serum which indi-
cates that all types of fibrils and not Aβ monomer or prefibrillar oligomers react with OC. B. Dot blot analysis of Aβ42 and 
polyQ36 prefibrillar oligomers and fibrils. Aβ42 and polyQ fibrils only stain with OC serum, while Aβ42 and polyQ prefibrillar 
oligomers only react with A11.Molecular Neurodegeneration 2007, 2:18 http://www.molecularneurodegeneration.com/content/2/1/18
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with I11 give the same staining pattern as A11 (Fig. 4B).
Similarly, rabbits vaccinated with IAPP fibrils give rise to
a fibril specific immune response that recognizes Aβ
fibrils and does not recognize monomer or prefibrillar oli-
gomers (Fig. 5). The resulting serum is called LOC (Like
OC). Taken together these results demonstrate that the
immune response to oligomer mimics and fibrils is pre-
dominantly conformation dependent and sequence inde-
pendent.
OC and LOC immunoreactivity in human AD tissue
We also investigated the distribution of OC and LOC
staining in human AD brain using two AD cases with Aβ
and NFT pathology. Figure 6 shows significant OC immu-
nolabeling in the hippocampus and temporal cortex. All
types of Aβ deposits stain with OC, including diffuse, neu-
Western blot analysis of Aβ42 fibrils and prefibrillar oligom- ers Figure 2
Western blot analysis of Aβ42 fibrils and prefibrillar 
oligomers. Aβ42 fibrils (F) and prefibrillar oligomers (O) 
were run on SDS polyacrylamide gels, transferred to nitro-
cellulose and probed with 6E10, 4G8, OC and A11 antibod-
ies as indicated at the top of the panel. Both fibrillar and 
prefibrillar oligomer samples contain bands that react with 
4G8 ranging from monomer up to the size of material that 
accumulates at the top of the gel. OC only stains the bands 
from fibrillar samples of approximately dimer and above. A11 
only stains the prefibrillar oligomer samples. 6E10 does not 
stain prefibrillar Aβ oligomer samples formed at pH 7.4 as 
previously reported [22].
Solubility and size distribution of fibrillar Aβ42 oligomers  under physiological conditions Figure 3
Solubility and size distribution of fibrillar Aβ42 oli-
gomers under physiological conditions. A. Aβ42 aggre-
gates were prepared in HFIP-H20 and DMSO-F12 medium as 
described in Materials and Methods and centrifuged at 
100,000 × G for 1 hr. The supernatant and pellet fractions 
were separated and the pellet resuspended in an equal vol-
ume of PBS. Aliquots of the supernatant and pellet were dot-
ted on nitrocellulose and probed with OC antisera. Both the 
soluble and insoluble fractions contain significant amounts of 
OC reactive material. B. Aβ42 aggregates formed in DMSO 
were fractionated by size exclusion chromatography on a 
Toso-Haas 2000 SWXL column, 1 minute fractions collected 
and dotted on nitrocellulose and probed with OC antisera. 
The elution profile detected by UV absorbance is shown in 
the top panel. The bottom panel shows the OC immunore-
activity which is detected in fractions from 8–14 minutes, 
indicating that low MW Aβ oligomers are immunoreactive 
with OC. The arrows indicate the positions of the void vol-
ume (Vo), included volume (Vi) and the elution positions of 
molecular weight standards.Molecular Neurodegeneration 2007, 2:18 http://www.molecularneurodegeneration.com/content/2/1/18
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ritic and cored plaques (Fig. 6) and cerebrovascular amy-
loid deposits (data not shown). Therefore, OC staining of
diffuse amyloid deposits indicates that they share the
fibrillar immunological structure of other amyloid depos-
its even though they do not stain with "fibril specific"
dyes, such as thioflavin S. Intracellular NFTs do not stain
with OC, even though it has been suggested that they con-
tain local β-sheet character [24]. Immunolabeling was vir-
tually abolished when the antibody was incubated with a
100-fold concentration of the fibrillar antigen prior to
incubation with the tissue (Fig. 6E, F). We next compared
OC and LOC immunoreactivity by confocal microscopy
as both antibodies recognize similar assembly states of
Aβ. The staining patterns of the two antibodies overlap
significantly within plaques of an AD case since most of
the fluorescent signals are coincident in the merged image
(Fig. 6G–I). Since LOC is raised against IAPP, this indi-
cates that the plaque staining is conformation dependent
and not due to a small amount of linear Aβ sequence spe-
cific antibodies that may contaminate OC.
Lysates of human AD brain were also analyzed biochemi-
cally with OC. OC immunoreactivity was found in the Tri-
ton X-100 100,000 × G insoluble fraction of all AD
patients examined (Fig. 7). This appeared as very high
MW material that sticks at the top of the gel or in the stack-
Comparison of LOC and OC antisera specificity Figure 5
Comparison of LOC and OC antisera specificity. Aβ 
monomer, prefibrillar oligomers and fibrils were spotted on 
nitrocellulose strips and probed with LOC and OC antisera. 
Both LOC and OC react only with fibrillar samples.
Comparison of A11 and I11 antibody specificity Figure 4
Comparison of A11 and I11 antibody specificity. A. 
Dot blots. Aβ monomer, Aβ prefibrillar oligomers (prepared 
in HFIP-H20, pH 2.5), Aβ fibrils and α-synuclein and IAPP 
prefibrillar oligomers were spotted on nitrocellulose strips 
and probed with A11, I11 and 6E10 as a control. A11 and I11 
antibodies demonstrate the same specificity for prefibrillar 
oligomers and do not react with monomer or fibrils. 6E10 
stains the Aβ-containing samples, including prefibrillar oli-
gomers formed at acid pH. B. Western blots. Prefibrillar oli-
gomer samples of calcitonin (Lane 1), insulin (Lane 2) and 
prion peptide 106–126 (Lane 3) were probed with A11 and 
I11, which give the same staining pattern.Molecular Neurodegeneration 2007, 2:18 http://www.molecularneurodegeneration.com/content/2/1/18
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ing gel after boiling in SDS sample buffer. After stripping
and reprobing, this high MW material also stains with
4G8 (anti-Aβ17–28) antibody. No OC staining was
observed in the Triton X-100 soluble fraction, indicating
that OC does not recognize APP and that the level of
fibrillar oligomers in this fraction is below the limit of
detection by this method (data not shown). The insoluble
fraction was also dissolved in formic acid and dried prior
to SDS gel electrophoresis. After formic acid treatment,
Western blot analysis of Triton X-100 insoluble fractions  from human AD brain lysates Figure 7
Western blot analysis of Triton X-100 insoluble frac-
tions from human AD brain lysates. Frontal cortex sam-
ples, either untreated or formic acid treated, from 6 
individual AD brains were dissolved in SDS sample buffer and 
electrophoresed on polyacrylamide gels and probed with OC 
or 4G8 as a control. Upper panels: For untreated samples, 
both OC and 4G8 detect high molecular weight material that 
accumulates at the top of the gel. Bottom panels: After for-
mic acid treatment, 4G8 detects some lower MW bands in 
addition to formic acid resistant high MW material, while the 
staining by OC is abolished, indicating that the staining is con-
formation dependent.
Immunolabeling characteristics of OC in an AD case and pre- absorption controls Figure 6
Immunolabeling characteristics of OC in an AD case 
and preabsorption controls. Extensive OC labeling was 
observed in the hippocampus (A), subiculum (B) and frontal 
cortex (C) in AD. A higher magnification photograph illus-
trates that OC positive deposits were dense and consisted of 
fine fibrillar material (D). Preabsorption with a 100-fold con-
centration of OC antigen leads to a significant reduction in 
immunolabeling in the frontal cortex (E &F). Significant over-
lap was observed between OC positive immunoreactivity 
(Red – G) and LOC positive immunoreactivity (Green-H) 
suggesting that the two antibodies recognize similar deposits 
(Overlap is yellow – I). Magnification in A, B, C – 1.25×, D – 
20×, E, F – 4× and G, H, I – 40×.Molecular Neurodegeneration 2007, 2:18 http://www.molecularneurodegeneration.com/content/2/1/18
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OC staining is abolished although 4G8 staining is
retained after stripping and reprobing, indicating that the
staining is conformation dependent. The 4G8 staining
reveals that formic acid treatment has a small effect on
breaking down the high MW material with more immu-
noreactivity at the top of the running gel and a small
amount of low MW Aβ immunoreactivity. Interestingly,
the OC immunoreactivity is insensitive to formic acid
treatment, typically used to enhance Aβ immunostaining,
after fixation of human AD brain tissue with paraformal-
dehyde. The immunoreactivity is insensitive to pretreat-
ment of sections with up to 90% formic acid (data not
shown).
OC staining of islet amyloid deposits
The broad specificity of OC for different types of amyloid
fibrils suggests that it may have broad utility in staining
different types of amyloid deposits. We also examined the
OC staining of islet amyloid deposits in the pancreas of
human IAPP transgenic mouse model of type II diabetes
[25]. OC stains intra and extracellular IAPP amyloid
deposits, indicating that the IAPP deposits display the
same fibril related generic epitope in vivo that they display
in vitro (Fig. 8). Together, these results indicate that the
broad fibril specific immunoreactivity of OC may be use-
ful for identifying a number of different types of amyloid
deposits in human disease.
Discussion
Amyloidogenic proteins and peptides can adopt a number
of distinct assembly states and a key issue is which of these
assembly states are more closely associated with patho-
genesis. Conformation dependent antibodies that specifi-
cally recognize these distinct assembly states offer the
potential of providing insight into which distinct assem-
bly states accumulate in disease and are pathologically sig-
nificant. We have prepared polyclonal antisera that
recognize a generic epitope specific to amyloid fibrils.
These antibodies are similar to other fibril specific anti-
bodies that have been previously reported [16,17]. One of
the major insights we have gained from examining the
properties of OC polyclonal antiserum and comparing it
to A11, is that there are at least two distinct types of amy-
loid oligomers: prefibrillar oligomers and fibrillar oli-
gomers. The idea of fibrillar oligomers may seem counter
intuitive because fibrils are often thought of as large insol-
uble structures, but the fact that OC recognizes small sol-
uble oligomers in the range of dimers to 250 kDa that are
not recognized by A11 indicates that these oligomeric spe-
cies are conformationally related to fibrils and conforma-
tionally distinct from prefibrillar oligomers. It is not
surprising that small fibrillar oligomers or pieces of fibrils
exist, because it is known that fibril assembly is a nuclea-
tion-dependent process and these soluble fibrillar oli-
gomers may represent fibril nuclei or seeds.
The fact that the epitopes recognized by OC and A11 are
generic and mutually exclusive indicate that the confor-
mational difference between fibrils and prefibrillar oli-
gomers is a widespread and fundamental distinction for
many different types of amyloids. This fundamental con-
formational difference forms an ideal and rational basis
for the nomenclature of amyloid assembly states. We pro-
pose that oligomers can be classified as at least two dis-
tinct types: prefibrillar oligomers and fibrillar oligomers
(Fig. 9). Prefibrillar oligomers are defined as an assembly
state that can ultimately convert to a fibrillar state by con-
certed or "en bloc" conformational conversion, while
fibrillar oligomers grow predominantly by addition of
monomer to the ends without undergoing further confor-
mational change. This elongation would involve a confor-
mation conversion at the level of the monomer. The
distinction between a fibrillar oligomer and a fibril is on
the basis of size and it seems likely that there is a contin-
uous distribution of potential sizes that vary by a single
monomeric subunit. There is no obvious demarcation
OC staining of pancreatic section from Tg mouse model of  type II diabetes expressing human IAPP (obese hemizygous  human IAPP transgenic mouse) Figure 8
OC staining of pancreatic section from Tg mouse 
model of type II diabetes expressing human IAPP 
(obese hemizygous human IAPP transgenic mouse). 
OC labeling (red) was detected within the islets in insulin-
positive (green) beta cells and in the extracellular amyloid 
deposits.Molecular Neurodegeneration 2007, 2:18 http://www.molecularneurodegeneration.com/content/2/1/18
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between fibrillar oligomers and fibrils, suggesting that the
distinction is necessarily arbitrary and operational. This
does not imply that size is not important pathologically as
small oligomers may have more diffusional freedom than
large fibrils and therefore may be able to move more freely
and bind reversibly to cellular targets.
The size of amyloid oligomers is not a reliable indicator of
their conformation or aggregation state. Prefibrillar oli-
gomers and fibrillar oligomers display broadly overlap-
ping size distributions, yet they are conformationally
distinct by virtue of the fact that they display mutually
exclusive epitopes. Since soluble amyloid oligomers are
widely believed to represent the primary pathological spe-
cies rather than insoluble amyloid fibrils, this raises the
question of which type of oligomer is important for
pathogenesis and whether prefibrillar and fibrillar oli-
gomers have distinct pathogenic mechanisms. Prefibrillar
oligomers have been reported in human AD brain [19]. It
is not yet clear whether fibrillar oligomer exist in human
AD brain and whether this correlates with pathology, but
this is the subject of further studies. Our results also sug-
gest that a lack of staining with thioflavin dyes and Congo
red may not be a reliable indicator of non-fibrillar confor-
mation. These dyes do not stain diffuse amyloid deposits
although all amyloid deposits including diffuse plaques
stain with OC, indicating that they display the fibril-spe-
cific epitope. It has been suggested that insoluble amyloid
plaques may represent a reservoir for soluble oligomer
production. If so, our data would suggest that this would
be a source of fibrillar oligomers rather than prefibrillar
oligomers, since all types of amyloid plaque deposits stain
intensely with OC.
Recent evidence indicates that prefibrillar oligomers are
not an obligate intermediate for amyloid fibril formation
and that they represent alternative aggregation pathways
and in vitro. Fibrils form under conditions that do not
support the formation of prefibrillar oligomers and drugs
that inhibit prefibrillar oligomer formation have no effect
on fibril formation or they actually promote fibril forma-
tion [22,26]. If prefibrillar oligomers are not obligate
intermediates for fibril formation in vivo, this would sug-
gest that amyloid fibrils could deposit without forming
prefibrillar oligomers. If prefibrillar oligomers are the pri-
mary toxic species, the direct formation of fibrils in the
absence of prefibrillar oligomers could explain why some
cognitively normal individuals have large amounts of
insoluble amyloid fibrils.
We also investigated whether the conformation depend-
ent immune response that gives rise to antibodies that rec-
ognize generic epitopes associated with distinct
aggregations states is independent of the peptide sequence
used as an antigen. We immunized rabbits with oligomer
mimics and amyloid fibrils derived from the islet amyloid
polypeptide and compared the specificity of the immune
response to antibodies elicited in response to Aβ derived
oligomer mimics and amyloid fibrils. We found that the
resulting immune sera are functionally equivalent with
the islet oligomer mimic antiserum, I11, recognizing the
same prefibrillar oligomers as A11 and the islet fibril anti-
bodies, LOC recognizing the same fibrillar epitope as OC.
This suggests that the immune response to amyloid aggre-
gates is predominantly conformation dependent, rather
than sequence specific. This observation may have some
practical utility. The staining of Aβ amyloid plaques with
LOC rules out the possibility that the plaque staining is
due to residual Aβ sequence specific immunoreactivity. It
Schematic representation of the distinct types of amyloid oli- gomers and their relationships to amyloid fibrils Figure 9
Schematic representation of the distinct types of 
amyloid oligomers and their relationships to amyloid 
fibrils. Amyloid aggregation pathways begin with misfolded 
amyloidogenic monomer (top) and can diverge in two direc-
tions depending on which conformation it adopts. It can 
aggregate to form prefibrillar oligomers by adopting the con-
formation recognized by A11 (left pathway). These prefibril-
lar oligomers then align to form protofibrils (not shown) and 
undergo another conformation change "en bloc" to form 
fibrils. They are termed prefibrillar oligomers because they 
are transient intermediates that ultimately become fibrils. 
Alternatively, amyloidogenic monomer can aggregate to 
adopt a fibrillar conformation recognized by OC antibody 
(right pathway). The resulting fibrillar oligomers may repre-
sent fibril nuclei which are the minimal stable aggregate that 
is capable of elongating by recruiting additional monomers. 
Addition of monomers on to the ends of fibrillar oligomers 
and fibrils result in fibril growth. The distinction between 
fibrillar oligomers and fibrils is based on an arbitrary size dif-
ference as no conformation difference is apparent. Fibrils 
may be distinct from fibrillar oligomers on the basis of their 
content of multiple protofilaments (not shown) but this does 
not necessarily imply a necessary conformation difference in 
their integral peptide constituents.Molecular Neurodegeneration 2007, 2:18 http://www.molecularneurodegeneration.com/content/2/1/18
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also suggests the possibility that oligomers and fibrils may
be specifically targeted by vaccination with non-human
amyloid sequences that could give rise to a therapeutic
immune response while avoiding potential autoimmune
complications.
Conclusion
Fibrils and fibrillar amyloid oligomers display a unique
generic epitope that is distinct from the generic epitope
displayed by prefibrillar oligomers. Conformation
dependent antibodies specific for these generic epitopes
may have broad utility for specifically targeting these dis-
tinct aggregation states in amyloid related degenerative
diseases.
Methods
Antigen and antibody preparation
Fibril antigens were prepared by stirring 2 mg/ml Aβ42
peptide in 50% HFIP/H2O, 0.02% sodium azide for 7
days. Afterwards, the HFIP was evaporated under a stream
of nitrogen and the sample was stirred for an additional 7
days and dialyzed against PBS (molecular weight cut off
10,000 Da). The resulting fibrils were checked by EM and
the purity was confirmed by the absence of oligomers
using anti-oligomer antibody. The same protocol was
used to prepare IAPP fibrils. Aβ and IAPP oligomer mim-
ics were prepared as previously described [27] The synthe-
sis of IAPP C-terminal thioester analog lacking cysteine
residues (KANTATAATQRLANFLVHSSNNFGAILSSTNVG-
SNTY-SR), was also carried out according to the methods
described [27]. The antigens were each used to immunize
two New Zealand white rabbits (Pacific Immunology
Corp., Ramona, CA, 92065) according to protocols
approved by IACUC. Each rabbit immunized with 500 µl
of antigen in complete Freund's adjuvant (CFA), and then
boosted twice at four week intervals with 500 µl of antigen
in Incomplete Freund's Adjuvant (IFA).
Fibril and oligomer preparation
Aβ fibrils and fibrillar oligomers were prepared by dissolv-
ing 0.3 mg of lyophilized Aβ42 in 150 ul of hexafluoro-2-
propanol (HFIP) for 10–20 minutes at room temperature.
The resulting Aβ solution was added to DD H2O in a sili-
conized Eppendorf tube to 80 uM concentration. After
10–20 min incubation at room temperature, the samples
were centrifuged for 15 min. at 14,000 × G and the super-
natant fraction (pH 2.8–3.5) was transferred to a new sil-
iconized tube and subjected to a gentle stream of N2 for 10
min to evaporate the HFIP. The sample was then stirred at
500 RPM using a Teflon coated micro stir bar for 24 hours
at 22°C. This method was originally reported for prepar-
ing A11 positive prefibrillar oligomers [19], but more
recent work indicates that it also produces fibrillar oli-
gomers that are OC positive. Fibrils were separated from
fibrillar Aβ42 oligomers by centrifuged at 100,000 × G for
1 hour at 4°C. The supernatant containing fibrillar oli-
gomers and pellet fraction containing fibrils were sepa-
rated and collected. The pellets were resuspended in an
equal volume of H2O. Alternatively, 1 mg of lyophilized
Aβ42 was dissolved in 200 µl of DMSO and incubated at
room temperature for 10–15 minutes to form fibrillar oli-
gomers. The fibrillar oligomers in DMSO were fraction-
ated according to size using a TSK-GEL SuperSW2000
column (Tosoh Bioscience LLC) in 10 mM Phosphate, pH
7.4 at a flow rate of 0.3 ml/min.
Prefibrillar oligomers that are OC negative were prepared
as previously described [22]. Aβ42 stock solutions (2
mM) were prepared by dissolving the lyophilized peptide
in 100 mM NaOH followed by water bath sonication for
30 s. The oligomerization reaction was initiated by dilut-
ing the stock solution in phosphate buffered saline (PBS),
pH = 7.4, 0.02% sodium azide (45 µM final Aβ42 concen-
tration, final pH = 7.4) and incubated at room tempera-
ture for up to 15 days. Oligomer formation was
monitored by dot blot with A11 and OC polyclonals.
ADDLs were prepared according to Lambert et al [23].
Aβ42 peptide was initially incubated in HFIP at room
temperature for 1 hour. The HFIP was evaporated under a
gentle stream of N2. The remaining Aβ42 was dissolved in
anhydrous DMSO at 5 mM, diluted into cold phenol red-
free F12 medium and aged at 4°C for 24 hours. The final
peptide concentration was 80 µM.
Q36 fibrils were prepared by dissolving Q36 in 10 mM
HEPES/100 mM NaCl at a concentration of 45 µM and
incubating with stirring at 25 C for 6 days. Fibril forma-
tion was confirmed by EM and ThT. Q36 oligomers were
prepared by dissolving Q36 in 1:1 (vol:vol) TFA:HFIP at 2
mM and diluting it to 45 µM in PBS and incubating with
stirring for 6 days. Oligomer formation was confirmed
with A11 antibody.
ELISA, dot blot, Western blot assays and 
Immunohistochemistry
ELISA, dot blot and western blots assays were done as pre-
viously described [27]. Brain tissue from autopsy cases
was provided by the University of California Alzheimer's
Disease Research Center and the Institute for Brain Aging
& Dementia Brain Tissue Resource. For single-labeling
experiments, 50 µm 4% paraformaldehyde-fixed sections
containing the hippocampus and entorhinal cortex or the
midfrontal cortex from an AD case (Case #1 – 65 year old
female, 7.4 hour post mortem interval, MMSE = 21 15
months prior to death with a Braak & Braak stage of VI)
were washed with 0.1 M Tris-buffered saline (TBS), pH
7.5, and then pretreated with 3% hydrogen peroxide in
10% methanol to block endogenous peroxidase activity.
Sections were subsequently washed in TBS with 0.1% Tri-Molecular Neurodegeneration 2007, 2:18 http://www.molecularneurodegeneration.com/content/2/1/18
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ton X-100 (TBS-A) and then blocked for thirty minutes in
TBS-A with 3% bovine serum albumin (TBS-B). In a series
of preliminary studies, the effects of different concentra-
tions of formic acid during a pretreatment phase was
determined to have little effect on the extent or intensity
of OC labeling of fixed tissue (data not shown) and thus
this step was eliminated from the protocol. Sections were
incubated overnight at room temperature in OC at a dilu-
tion of 1:10,000. Following two washes with TBS-A and a
wash in TBS-B, sections were incubated in either goat anti-
mouse or goat anti-rabbit biotinylated anti-IgG and then
in avidin biotin complex (ABC) (Vector Laboratories, Bur-
lingame, CA, USA). Antibodies were visualized using 3,3'-
diaminobenzidine (DAB, Vector Laboratories). For quan-
tification experiments, the frontal cortex from all cases
used for quantification was immunostained in single
experiments to reduce variability in the image analysis
procedures and all immunohistochemical procedures
were identical for the OC antibody. To determine the spe-
cificity of the OC antibody, IgG purified serum at a con-
centration of 1:10,000 was preincubated in 10× and 100×
concentration of OC peptide for 2 hours at RT. Subse-
quently, a section from the midfrontal cortex was incu-
bated in the OC antibody/peptide solution and processed
for immunohistochemistry. Sections were counterstained
with cresyl violet.
Mouse strain and tissue collection
Hemizygous human IAPP transgenic mice (FVB-
tg(IAPP)6Jdm/-Avy/A) were characterized in details else-
where [28]. For this study we used 24 wk old mice. Before
collection of mouse pancreata, the heart was perfused
with 10 ml of 4% paraformaldehyde. The pancreas was
dissected in cold PBS, fat and lymph nodes trimmed, the
pancreas weighed, fixed in 4% paraformaldehyde at 4°C
for 24 h then frozen in OCT.
Immunofluorescence and confocal microscopy
An additional AD case was used for confocal studies. Case
#2 was a 95 year old female with a post mortem interval
of 5.5 hours and a MMSE score of 12, 6.3 months prior to
death. Sections containing the midfrontal cortex were
incubated in OC overnight (1: 5,000) and positive labe-
ling was detected using anti-rabbit IgG Alexa Fluor 568
(Molecular Probes, Eugene, OR; 1:200). Alexa Fluoro 488
(Molecular Probes, Eugene, OR; 1:200) was subsequently
used to visualize LOC (1:5,000). The order of the primary
antibodies was also reversed in additional experiments
and the results were similar. Because both antibodies were
raised in the same species (rabbit) an intervening formal-
dehyde treatment was used between the first and second
immunolabel [29]. Sections were allowed to dry on slides
prior to rehydration and coverslipping with VectaShield
(Vector Laboratories, Burlingame, CA, USA). Confocal
images were collected on an Olympus IX70 inverted
microscope and a BioRad Radiance 2000 Laser Scanning
System using a 40, 60 or 100× objective for image analy-
sis. Each antibody label was excited and scanned using
lambda strobing and barrier filters at 510 and 480 nm. A
z-series scan at either 0.5 or 1 µm intervals was captured
to determine the spatial colocalization characteristics of
OC with LOC.
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